Gland Pharma Limited has signaled a steady hand on its governance helm with two independent directors taking the stage on the company’s board. In a move conveyed to the exchanges, shareholders via postal ballot approved the re-appointment of Udo Jahannes Vetter as an Independent Director for a second five-year term, effective July 21, 2026, through July 20, 2031, along with the approval of commission on profits as remuneration. Simultaneously, William Robert Keller was appointed as an Independent Director for five consecutive years, with effect from June 15, 2026, to June 14, 2031, also with remuneration linked to profits. These changes underscore Gland Pharma’s emphasis on seasoned, independent oversight as it heads into a new chapter of growth.